ライフサイエンスコーパス: isoniazid

1 his is the target of the first line pro-drug isoniazid.

2 is the target for the frontline anti-TB drug isoniazid.

3 hages and accumulated in lysosomes releasing Isoniazid.

4 plus on sputa was 4% for rifampin and 2% for isoniazid.

5 -NAD adduct formed by the tuberculosis drug, isoniazid.

6 sessed in participants who began rifapentine-isoniazid.

7 re anchored by two antibiotics, rifampin and isoniazid.

8 ted dormancy and sensitized the organisms to isoniazid.

9 ized 1:1 to 10 mg/kg/d rifampin or 5 mg/kg/d isoniazid.

10 s similar among people receiving rifampin or isoniazid.

11 rst-line antitubercular drugs rifampicin and isoniazid.

12 In children <3 years old, isoniazid 0- to 24-hour area under the concentration-tim

13 QC ranges were established for 11 drugs: isoniazid (0.03 to 0.12 mug/ml), rifampin (0.03 to 0.25

14 a 1-month regimen of daily rifapentine plus isoniazid (1-month group) with 9 months of isoniazid alo

15 men who died from liver failure had received isoniazid [1 in each group]).

16 Isoniazid 10-15 mg/kg daily had similar activity against

17 complex disease using IS-enabled combination isoniazid 150 mg/rifampin 300 mg (IS-Rifamate).

18 combination tablets [75 mg rifampicin, 50 mg isoniazid, 150 mg pyrazinamide]) and two alternative dos

19 ontrol regimen (10 mg/kg rifampicin, 5 mg/kg isoniazid, 25 mg/kg pyrazinamide, and 15-20 mg/kg ethamb

20 nuation phase of treatment, prescribed daily isoniazid 300 mg and rifampin 600 mg, used IS-Rifamate.

21 patients awaiting liver transplantation and isoniazid (300 mg q24h for 9 months) initiated post-tran

22 months of self-administered rifapentine and isoniazid (3HP) under various TTT scenarios. Specificall

23 an inhA mutation were randomized to receive isoniazid 5, 10 or 15 mg/kg daily for 7 days (inhA group

24 ses of once-weekly rifapentine (900 mg) plus isoniazid (900 mg) could greatly improve tuberculosis co

25 then began once-weekly rifapentine (900 mg)-isoniazid (900 mg) for 12 weeks.

26 r with 4 months of rifampin than 9 months of isoniazid (95% vs 68%, P < .005).

27 phenotypic reference were 100% and 100% for isoniazid, 98.4% and 50% for rifampin (specificity incre

28 BI) with 9 months of self-administered daily isoniazid (9H) has historically been low (<50%) among Ne

29 dormancy and became highly nonresponsive to isoniazid, a major constituent of directly observed trea

30 ted with the combination of RUTI vaccine and isoniazid, according to the dosage strategy described in

31 ampin appears to be safe and as effective as isoniazid across many populations with health conditions

32 rikingly, # 6513745 displayed synergism with isoniazid against M. marinum in murine macrophages, wher

33 The activity of high-dose isoniazid against strains with katG mutations will be ex

34 s isoniazid (1-month group) with 9 months of isoniazid alone (9-month group) in HIV-infected patients

35 lus isoniazid was noninferior to 9 months of isoniazid alone for preventing active TB.

36 lus isoniazid was noninferior to 9 months of isoniazid alone for preventing tuberculosis in HIV-infec

37 e events were less common with rifampin than isoniazid among people living with HIV (risk difference:

38 of four-months of rifampin vs nine-months of isoniazid among people living with HIV or other health c

39 or 12 weeks, followed by 14 weeks of 5 mg/kg isoniazid and 10 mg/kg rifampicin per day.

40 ntal treatments were given with oral 5 mg/kg isoniazid and 25 mg/kg pyrazinamide per day for 12 weeks

41 dy period with 46% prescribed nine months of isoniazid and 43% four months of rifampin.

42 (PY); 0.53 per 100 PY in those who initiated isoniazid and 6.52 per 100 PY for those who did not (adj

43 The majority of patients received isoniazid and a rifamycin as part of multidrug regimen.

44 eek 11 (after the third dose of rifapentine)-isoniazid and at week 16 after the eighth dose.

45 rved that co-treatment with the anti-TB drug isoniazid and bergenin produces additive effects and sig

46 is strongly up-regulated upon treatment with isoniazid and ethambutol is the iniBAC operon.

47 We identified isoniazid and ethionamide resistance mutations on line p

48 h species typing and resistance to rifampin, isoniazid and fluoroquinolone antibiotics.

49 The optimal dose of isoniazid and its individual contribution to efficacy ag

50 , interfere with the bactericidal potency of isoniazid and moxifloxacin.

51 olates, including four that are resistant to isoniazid and one that is resistant to both isoniazid an

52 MAX) = 400 ng/ml)) and different half-lives (isoniazid and pyrazinamide (C(MAX) = 28,900 ng/ml and T(

53 Isoniazid and pyrazinamide concentrations were 14.6 (95%

54 ) positive CD271(+) BM-MSCs after 90 days of isoniazid and pyrazinamide therapy that rendered animal'

55 rapy protocols including drugs with similar (isoniazid and rifampicin (C(MAX) = 400 ng/ml)) and diffe

56 Isoniazid and rifampicin are two of the most powerful fi

57 d electrochemical approaches for analysis of isoniazid and rifampicin has also been presented.

58 The most frequent mutation among isoniazid and rifampicin isolates was S315T in katG and

59 The bactericidal drugs isoniazid and rifampicin kill greater than 99% of expone

60 We estimated the incidence of acquired isoniazid and rifampicin resistance in rifampicin-suscep

61 The sensitivities and specificities for isoniazid and rifampicin resistance of the tools were hi

62 atG and rpoB genes, conferring resistance to isoniazid and rifampicin respectively.

63 based sensory designs for electroanalysis of isoniazid and rifampicin, the most important medicines f

64 e genetic mutations conferring resistance to isoniazid and rifampicin.

65 combination therapies with 3 to 4 months of isoniazid and rifampicin.

66 irmed TB disease with resistance to at least isoniazid and rifampicin.

67 isoniazid and one that is resistant to both isoniazid and rifampicin.

68 ally infected mice exhibit tolerance to both isoniazid and rifampin to a degree proportional to the a

69 clarithromycin, or kanamycin, in addition to isoniazid and rifampin.

70 r resistance to anti-tuberculosis (TB) drugs isoniazid and rifampin.

71 osis (MDR-TB) is simultaneously resistant to isoniazid and rifampin.

72 reatment of TBI with 3 months of once-weekly isoniazid and rifapentine (3HP) administered under direc

73 r, although a 12-week regimen of once-weekly isoniazid and rifapentine (3HP) is currently recommended

74 egimen, 12 weekly doses of directly observed isoniazid and rifapentine (3HP), is as efficacious as 9

75 Participants received once-weekly isoniazid and rifapentine by direct observation, self-ad

76 eatment completion and safety of once-weekly isoniazid and rifapentine by self-administration versus

77 s aged 0-17 years, a treat-all approach with isoniazid and rifapentine compared with a treat-TST-only

78 Once-weekly isoniazid and rifapentine for 12 doses is effective but

79 support using self-administered, once-weekly isoniazid and rifapentine to treat latent tuberculosis i

80 for people older than 64 years treated with isoniazid and rifapentine.

81 dicts the efficacy of the combined action of isoniazid and RUTI vaccine in a specific digital populat

82 polymorphs of the well-known pharmaceutical isoniazid and show that CSP provides the structure of th

83 nd clofazimine followed by 2 mo of rifampin, isoniazid, and clofazimine.

84 are responsible for resistance to rifampin, isoniazid, and fluoroquinolone, respectively.

85 idence of DILI (flucloxacillin, amoxicillin, isoniazid, and nitroso-sulfamethoxazole) to characterize

86 Among 404 participants, rifampicin, isoniazid, and pyrazinamide concentrations were subthera

87 intensively sampled to determine rifampicin, isoniazid, and pyrazinamide plasma concentrations after

88 Isoniazid- and moxifloxacin-induced mycobacterial death

89 h 1 (with similar results for rifampicin and isoniazid at month 5).

90 netic sampling at week 8 (before rifapentine-isoniazid), at week 11 (after the third dose of rifapent

91 mechanism-agnostic machine learning models (isoniazid AUC = 0.93) while enabling a biochemical inter

92 n or rifapentine are as effective as longer, isoniazid-based regimens, and there is a promising vacci

93 ivo efficacy equal to the first-line TB drug isoniazid, both as a monotherapy and in combination ther

94 micking isoniazid in lung lesion homogenate (isoniazid C(MAX) = 1,200 ng/ml, T(MAX) = 2.2 hr and T(1/

95 suggest 12 doses of once-weekly rifapentine-isoniazid can be given for tuberculosis prophylaxis to p

96 For patients with isoniazid Cmax >4.6 mg/L, higher isoniazid exposures wer

97 ARS identified negative interactions between isoniazid Cmax and rifampicin Cmax/MIC ratio on 2-month

98 PK/PD analyses using MARS identified isoniazid Cmax and rifampicin Cmax/MIC thresholds below

99 If isoniazid Cmax was <4.6 mg/L and rifampicin Cmax/MIC <28

100 [95% CI, 2.03-10.39]) for 24 weeks of daily isoniazid compared with placebo.

101 s <4.6 mg/L and rifampicin Cmax/MIC <28, the isoniazid concentration had an antagonistic effect on cu

102 t because of the high rates of inappropriate isoniazid-containing regimens, and treatment non-adheren

103 daily for 2 months, followed by rifampin and isoniazid daily for 4 months.

104 Isoniazid data were available from 156 countries or terr

105 into lysosomes for synergistic lysosomal and Isoniazid destruction of Mtb.

106 h this ratio varied by day after rifapentine-isoniazid dose.

107 were applied to the A5279/Brief Rifapentine-Isoniazid Efficacy for TB Prevention study, and design c

108 sses of polar analytes including ethambutol, isoniazid, ephedrine, and gemcitabine in biological matr

109 Antituberculosis therapy (rifampicin, isoniazid, ethambutol and pyrazinamide) was initiated up

110 ystematic empirical treatment with rifampin, isoniazid, ethambutol, and pyrazinamide daily for 2 mont

111 The predicted resistance to rifampicin and isoniazid exceeded 90% sensitivity and specificity but w

112 tients with isoniazid Cmax >4.6 mg/L, higher isoniazid exposures were associated with improved rates

113 Weekly rifapentine plus isoniazid for 3 months (3HP) is as effective as daily is

114 for 3 months (3HP) is as effective as daily isoniazid for 9 months (9H) for latent tuberculosis infe

115 Define the optimal dose of isoniazid for patients with isoniazid-resistant TB media

116 Patients who received high-dose isoniazid had a faster time to culture conversion and hi

117 Isoniazid had concentration-dependent antagonism with ri

118 pin was more often or similarly completed to isoniazid in all populations.

119 esistant tuberculosis who received high-dose isoniazid in Haiti.

120 ndomized clinical trial (RCT) of 24 weeks of isoniazid in individuals with pulmonary fibrotic lesions

121 A monotherapy protocol mimicking isoniazid in lung lesion homogenate (isoniazid C(MAX) =

122 tion of rifampicin resistance often preceded isoniazid in our isolates.

123 nces the efficacy of front line anti-TB drug Isoniazid in the murine model of infection.

124 Rifapentine-isoniazid increased dolutegravir clearance by 36% (relat

125 Isoniazid induced a drug-tolerant persister population o

126 The bergenin co-treatment also reduced isoniazid-induced immune impairment; promoted long-lasti

127 ld Health Organization recommends the use of isoniazid (INH) alone or in combination with rifapentine

128 n detecting resistance to rifampin (RMP) and isoniazid (INH) and in detecting multidrug-resistant tub

129 obacteria in the presence of the antibiotics isoniazid (INH) and rifampicin (RIF), in an attempt to d

130 iency virus (PLWH) require TB treatment with isoniazid (INH) and rifampicin (RIF), which affect cytoc

131 Mycobacterium tuberculosis (MTB), and detect isoniazid (INH) and rifampin (RIF) resistance.

132 Mycobacterium tuberculosis (MTB) and detect isoniazid (INH) and rifampin (RIF) resistance.

133 ection of XDR-TB plus resistance to the drug isoniazid (INH) for point-of-care use.

134 Twelve-week rifapentine (RPT)/isoniazid (INH) is effective for LTBI but clinical exper

135 or the rapid detection of rifampin (RIF) and isoniazid (INH) resistance.

136 Isoniazid (INH) was the first synthesized drug that medi

137 CWs diagnosed with LTBI were offered 9-month isoniazid (INH), 4-month rifampin (RIF), weekly rifapent

138 ng resistance to four first-line drugs [i.e. isoniazid (INH), ethambutol (EMB), rifampicin (RIF), pyr

139 ) in the presence of its common interference isoniazid (INH), which are both found in drug samples.

140 We demonstrate that isoniazid (INH)-derived nanobiotics, alone or with addit

141 cted within 2 y), and recently infected with isoniazid (INH)-resistant strains.

142 s, acid stress, and the frontline antibiotic isoniazid (INH).

143 sis to the first-line anti-tuberculosis drug isoniazid (INH).

144 e (INH-R), and susceptible to rifampicin and isoniazid (INH-S + RIF-S).

145 Seven major TB drugs (rifampin [RIF], isoniazid [INH], linezolid [LZD], moxifloxacin [MFX], cl

146 Isoniazid is associated with higher rates of hepatotoxic

147 High-dose isoniazid is recommended in short-course regimens for mu

148 We also did this for isoniazid, kanamycin, ofloxacin, rifampicin, and strepto

149 mutations in genes conferring resistance to isoniazid (katG and inhA) and rifampin (rpoB).

150 ine tuberculosis treatments, specifically to isoniazid, leading to multi-drug-resistant tuberculosis.

151 fampicin <8 mg/L, pyrazinamide <35 mg/L, and isoniazid <3 mg/L.

152 erapeutic cutoffs were: rifampicin <8 ug/mL, isoniazid <3 ug/mL, and pyrazinamide <20 ug/mL.

153 determined as follows: rifampicin (<=0.125), isoniazid (<=0.25), ethambutol (<=2.0), moxifloxacin (<=

154 31% for 9 months of daily self-administered isoniazid (maximum dose, 300 mg; 9H-SAT).

155 ekly rifapentine (maximum dose, 900 mg) plus isoniazid (maximum dose, 900 mg) (3HP-DOT) and 31% for 9

156 romoter alone, for whom an increased dose of isoniazid may be considered.

157 This suggests high-dose isoniazid may have effectiveness even with phenotypic re

158 Addition of ATM inhibitor enhances isoniazid mediated Mtb clearance in macrophages as well

159 ive, 16 with isoniazid-sensitive and 41 with isoniazid mono-resistant or MDR TB, were enrolled at one

160 eline isolates (6.1%; 95% CI, 3.6%-9.6%) had isoniazid monoresistance (13 of 17 had an inhA promoter

161 Isoniazid monoresistance was detected in 5.2% of new cas

162 ntiretroviral therapy, and low prevalence of isoniazid monoresistance were associated with a low freq

163 infected with M tuberculosis; 5 million with isoniazid monoresistance, 2 million with MDR, and 100 00

164 f tuberculosis cases at a country level with isoniazid monoresistance, rifampicin monoresistance, mul

165 ine isolates were retrospectively tested for isoniazid monoresistance.

166 ratory specimens and is able to discriminate isoniazid-monoresistant cases from multidrug-resistant c

167 developed tuberculosis in 2014; 58 000 with isoniazid-monoresistant tuberculosis, 25 000 with MDR tu

168 xists for the efficacy and safety of 6-month isoniazid monotherapy, rifampicin monotherapy, and combi

169 To inhibit InhA, isoniazid must be activated by the catalase-peroxidase K

170 For isoniazid, mutations in the N-acetyltransferase 2 (NAT2)

171 The first group was treated with isoniazid only, while the second one was treated with th

172 a grade 3 AE vs 1 of 493 (0.2%) who received isoniazid only.

173 vs 3 of 434 (cumulative rate, 0.74%) in the isoniazid-only group, for a difference of -0.74% and an

174 ifapentine and isoniazid was as effective as isoniazid-only treatment for the prevention of tuberculo

175 f cysteine or other small thiols with either isoniazid or rifampicin prevents the formation of drug-t

176 owing an 8-fold higher activity than that of isoniazid or TAM16 given at 10 or 100 mg/kg, respectivel

177 ing p.Ser315Thr, which confers resistance to isoniazid, overwhelmingly arose before mutations that co

178 el to project lifetime costs and benefits of isoniazid PGT for drug-susceptible tuberculosis in Brazi

179 Isoniazid PGT improves health outcomes and would be cost

180 Our data suggest that isoniazid preclearance of M. tuberculosis bacilli has li

181 cinated with BCG after a six-month course of isoniazid preventative therapy.

182 (95% CI 3.5-7.8) for empirical group and for isoniazid preventive therapy (95% CI 3.4-7.8); absolute

183 med a phase I randomized controlled trial of isoniazid preventive therapy (IPT) before revaccination

184 Isoniazid preventive therapy (IPT) is widely used to pro

185 We also hypothesized that isoniazid preventive therapy (IPT) may revert LTBI diagn

186 Isoniazid preventive therapy (IPT) reduces mortality amo

187 Isoniazid preventive therapy (IPT) reduces mortality amo

188 annual follow-up examinations and secondary isoniazid preventive therapy (IPT), alone and in combina

189 early antiretroviral therapy (ART), 6-month isoniazid preventive therapy (IPT), or both among HIV-in

190 on to receive either empiric TB treatment or isoniazid preventive therapy (IPT).

191 on to receive either empiric TB treatment or isoniazid preventive therapy (IPT).

192 Isoniazid preventive therapy as an adjunct to ART preven

193 The risks associated with initiation of isoniazid preventive therapy during pregnancy appeared t

194 pregnant women with HIV infection to receive isoniazid preventive therapy for 28 weeks, initiated eit

195 gramme scenario, a combination of continuous isoniazid preventive therapy for individuals on antiretr

196 y and empirical tuberculosis therapy) or the isoniazid preventive therapy group (antiretroviral thera

197 mpirical tuberculosis therapy and 426 to the isoniazid preventive therapy group.

198 rical group and 97 (23%) participants in the isoniazid preventive therapy group.

199 rical group and 46 (11%) participants in the isoniazid preventive therapy group.

200 Asymptomatic participants were offered isoniazid preventive therapy in both arms.

201 t would reduce early mortality compared with isoniazid preventive therapy in high-burden settings.

202 omparing empirical tuberculosis therapy with isoniazid preventive therapy in HIV-positive outpatients

203 t reduce mortality at 24 weeks compared with isoniazid preventive therapy in outpatient adults with a

204 ion of systematic tuberculosis screening and isoniazid preventive therapy in outpatients with advance

205 Isoniazid preventive therapy is recommended in HIV-posit

206 ve therapy group (antiretroviral therapy and isoniazid preventive therapy).

207 phases of a randomized, controlled trial of isoniazid preventive therapy.

208 CWs to be offered antiretroviral therapy and isoniazid preventive therapy.

209 -containing regimen: 2 mo of daily rifampin, isoniazid, pyrazinamide, and clofazimine followed by 2 m

210 Isoniazid, pyrazinamide, and ethambutol achieved higher

211 TB treatment, i.e., 2 mo of daily rifampin, isoniazid, pyrazinamide, and ethambutol followed by 4 mo

212 (PK/PD) simulation model including rifampin, isoniazid, pyrazinamide, and ethambutol was developed an

213 trapulmonary pharmacokinetics of rifampicin, isoniazid, pyrazinamide, and ethambutol, and explore rel

214 t treatment arms (63 to rifampicin 35 mg/kg, isoniazid, pyrazinamide, and ethambutol; 59 to rifampici

215 amide, and SQ109; 63 to rifampicin 10 mg/kg, isoniazid, pyrazinamide, and moxifloxacin; and 123 to th

216 azinamide, SQ109; 57 to rifampicin 20 mg/kg, isoniazid, pyrazinamide, and SQ109; 63 to rifampicin 10

217 , and ethambutol; 59 to rifampicin 10 mg/kg, isoniazid, pyrazinamide, SQ109; 57 to rifampicin 20 mg/k

218 s (OR, 0.53 [CrI, 0.36 to 0.78]), rifampicin-isoniazid-pyrazinamide regimens (OR, 0.35 [CrI, 0.19 to

219 m-sulfamethoxazole plus at least 12 weeks of isoniazid-pyridoxine (coformulated with trimethoprim-sul

220 (pyrazinamide, para-aminosalicylic acid, and isoniazid) recapitulates known AMR mechanisms and sugges

221 verse events could be minimised by using non-isoniazid regimens and, in adults older than 18 years, f

222 e existed for efficacy of weekly rifapentine-isoniazid regimens compared with no treatment (OR, 0.36

223 s (OR, 0.41 [CrI, 0.19 to 0.85]), rifampicin-isoniazid regimens of 3 to 4 months (OR, 0.53 [CrI, 0.36

224 d 53 previously included studies showed that isoniazid regimens of 6 months (odds ratio [OR], 0.65 [9

225 We examined the impact of isoniazid resistance and treatment regimen, including us

226 There was no significant association with isoniazid resistance and tSCC or initial treatment outco

227 Isoniazid resistance arose once and rifampin resistance

228 patients in 2018, whereas the prevalence of isoniazid resistance at global and regional levels is le

229 Isoniazid resistance is linked primarily to mutations in

230 iduals with smear-positive pulmonary TB with isoniazid resistance mediated by an inhA mutation were r

231 dings were caused by uncommon rifampicin and isoniazid resistance mutations.

232 ceptible cases (35 vs 29 days; P = .39), and isoniazid resistance was not associated with tSCC in mul

233 e 100% and 100%, respectively, and those for isoniazid resistance were 90.7% and 100%.

234 ing data for all genomic regions involved in isoniazid resistance were available for 4,563 patients.

235 del was used to determine the association of isoniazid resistance with tSCC.

236 estimated a 47% increase in the incidence of isoniazid resistance, a 152% increase in multidrug-resis

237 ds of successful outcome, despite high-level isoniazid resistance.

238 ts with pulmonary tuberculosis, 59 (25%) had isoniazid resistance.

239 treatment non-adherence, this would generate isoniazid resistance.

240 The infecting strain was isoniazid resistant and during treatment it stepwise acc

241 ere predefined as multidrug resistant (MDR), isoniazid resistant, rifampicin susceptible (INH-R), and

242 The median tSCC was similar for isoniazid-resistant and -susceptible cases (35 vs 29 day

243 culosis, and suggest there are more cases of isoniazid-resistant and multidrug-resistant (MDR) diseas

244 f multidrug-resistant TB (MDR-TB) as well as isoniazid-resistant but rifampin-susceptible TB.Methods:

245 ether treatment of patients with preexisting isoniazid-resistant disease with first-line anti-TB ther

246 We found that the isoniazid-resistant katG Ser315Thr mutation occurred mor

247 tivity was exhibited against rifampicin- and isoniazid-resistant M. tuberculosis strains with MIC val

248 possible exception of patients infected with isoniazid-resistant M. tuberculosis.

249 Patients with isoniazid-resistant pulmonary TB were recruited and foll

250 Two hundred thirty-nine patients with isoniazid-resistant pulmonary TB were recruited.

251 Early diagnosis and optimal treatment of isoniazid-resistant TB are urgently needed to avert the

252 optimal dose of isoniazid for patients with isoniazid-resistant TB mediated by inhA mutations.

253 In isoniazid-resistant TB, de novo emergence and reinfectio

254 contacts exposed to MDR-TB and treatment of isoniazid-resistant TB.

255 Early FQ use was higher in isoniazid-resistant than -susceptible cases (20% vs 10%;

256 Meta-analysis of patients with isoniazid-resistant tuberculosis (TB) given standard fir

257 Although patients with isoniazid-resistant tuberculosis had a high cure rate, t

258 Although isoniazid-resistant tuberculosis is more common than mul

259 A large isoniazid-resistant tuberculosis outbreak centred on Lon

260 Patients with isoniazid-resistant tuberculosis were treated with regim

261 urrence (n = 3) occurred among patients with isoniazid-resistant tuberculosis.

262 ed 6-month treatment regimen for people with isoniazid-resistant, rifampicin-susceptible TB (Hr-TB),

263 ase, of which 10.9% (95% UI:10.2%-11.8%) was isoniazid-resistant.

264 nd lung lesion homogenate were simulated for isoniazid, rifampicin and pyrazinamide and moxifloxacin.

265 henotypic resistance data across five drugs (isoniazid, rifampicin, ethambutol, pyrazinamide, and str

266 As these regimens omit isoniazid, rifampicin, fluoroquinolones and injectable a

267 ent with standard tuberculosis therapy (oral isoniazid, rifampicin, pyrazinamide, and ethambutol; HRZ

268 were treated and those with TBI were offered isoniazid-rifampicin preventive therapy for 3 months.

269 there was high between-child variability of isoniazid, rifampin, and pyrazinamide concentrations: 11

270 itubercular activity of the first-line drugs isoniazid, rifampin, and pyrazinamide in THP-1 cells.

271 by these regimens to the standard regimen of isoniazid, rifampin, and pyrazinamide, based on exponent

272 s slower than the standard 3-drug regimen of isoniazid, rifampin, and pyrazinamide.

273 lymorphisms (SNPs) that confer resistance to isoniazid, rifampin, ofloxacin, and moxifloxacin occur t

274 erculosis receiving standard 4-drug therapy (isoniazid, rifampin, pyrazinamide, and ethambutol) in Br

275 tect mutations associated with resistance to isoniazid, rifampin, quinolones and injectable drugs in

276 Once-weekly isoniazid-rifapentine by self-administered therapy (3HP-

277 e hospitalized or who died after >=1 dose of isoniazid-rifapentine for treatment of latent Mycobacter

278 s in katG, inhA promoter, and ahpC promoter (isoniazid), rpoB (rifampin), gyrA (fluoroquinolones), rr

279 , 4-month rifampin (RIF), weekly rifapentine/isoniazid (RPT/INH) for 12 weeks, or no treatment.

280 cavitary disease, 20% HIV-positive, 16 with isoniazid-sensitive and 41 with isoniazid mono-resistant

281 lase KatG, an activating enzyme required for isoniazid sensitivity, and upregulation of WhiB7, a tran

282 Isoniazid showed a tri-modal pattern with 14/17 strains

283 herence assessments against results of urine isoniazid tests collected during unannounced home visits

284 safety, efficacy, and appropriate timing of isoniazid therapy to prevent tuberculosis in pregnant wo

285 All 3 lineages developed isoniazid tolerance.

286 PGT was modeled to reduce isoniazid toxicity among slow NAT2 acetylators and reduc

287 cantly reduces bacterial loads compared with isoniazid treatment alone.

288 y these mutations or caused by ethambutol or isoniazid treatment may be relieved by iniBAC to increas

289 ophages, the addition of N-acetylcysteine to isoniazid treatment potentiated the killing of Mtb Furth

290 onsequently, the addition of rapamycin to an isoniazid treatment regimen successfully attained steril

291 ncentrations with versus without rifapentine-isoniazid was 0.53 (90% CI 0.49-0.56) though this ratio

292 ment with the combination of rifapentine and isoniazid was as effective as isoniazid-only treatment f

293 The 7-day early bactericidal activity of isoniazid was estimated as the average daily change in l

294 A 1-month regimen of rifapentine plus isoniazid was noninferior to 9 months of isoniazid alone

295 hat 3 months of once-weekly rifapentine plus isoniazid was noninferior to 9 months of isoniazid alone

296 susceptibility results for both rifampin and isoniazid were seen in 26% of MTBDRplus tests performed

297 ugs against tuberculosis (ie, rifampicin and isoniazid), which is called multidrug-resistant tubercul

298 Current frontline therapies include the drug isoniazid, which inhibits the essential NADH-dependent e

299 e risk difference for hepatoxicity comparing isoniazid with rifampin ranged from 3% to 7%, with a poo

300 ethambutol followed by 4 mo of rifampin and isoniazid, with a 4-mo clofazimine-containing regimen: 2

301 tine (3HP), is as efficacious as 9 months of isoniazid, with a greater completion rate (82% vs 69%);